Abstract
Idiopathic Myelofibrosis (MF) is an extremely rare condition in children. It has a very variable clinical spectrum. Cases of secondary myelofibrosis associated with Vitamin D deficiency and Systemic Lupus Erythematosus have been reported from India .In this case report, the authors describe clinical signs, laboratory findings and histologic features in a 6 month old infant with Idiopathic myelofibrosis.
References
Johnston J Martin. Myelofibrosis. Available from URL: http://www.emedicine.medscape.com/article/956806-overview. Accessed May 15 2009.
Naithani R, Tyagi S, Choudhry VP. Secondary myelofibrosis in children. J Pediatr Hematol Oncol. 2008;30:196–8.
Chandra J, Narayan S, Kumar P, et al. Myelofibrosis. Indian Pediatr. 1992;29:911–4.
Rani S, Maheshwari C, Singh T. Beohar PC.Idiopathic myelofibrosis. Indian Pediatr. 1984;21:817–20.
Narayan S, Chandra J, Sharma S, Aiyer H. Idiopathic Myelofibrosis in children. Indian JHemat and Blood Trans. 2000;18:100–1.
Bain BJ,Clark DM,Lampert IA,Wilkins BS. Myeloproliferative disorders.In Bain BJ,Clark DM,Lampert IA,Wilkins BS eds.Bone Marrow athology.Oxford,Blackwell Science,2000;202–208
Komura E, Tonetti C, Penard-Lacronique V. Role for the nuclear factor kappaB pathway in transforming growth factor-beta1 production in idiopathic myelofibrosis: possible relationship with FK506 binding protein 51 overexpression. Cancer Res. 2005;65:3281–9.
Stephan JL, Galambrun C, Dutour A. Myelofibrosis: an unusual presentation of vitamin D-deficient rickets. Eur J Pediatr. 1999;158:828–9.
Wolf BC, Neiman RS. Myelofibrosis with myeloid metaplasia: pathophysiologic implications of the correlation between bone marrow changes and progression of splenomegaly. Blood. 1985;65:803–9.
Agarwal BR, Bhalla K, Dalvi R, Currimbhoy ZE, Mehta KP. Myelofibrosis secondary to SLE and its reversal on steroid therapy. Indian Pediatr. 1995;32:1207–10.
Kerbauy DM, Gooley TA, Sale GE. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant. 2007;13:355–65.
Hasselbalch HC, Bjerrum OW, Jensen BA, et al. Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis. Am J Hematol. 2003;74:238–42.
Mesa RA, Nagorney DS, Schwager S. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer. 2006;107:361–70.
Conflict of Interest
None.
Role of Funding Source
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bavikar, R.R., Kulkarni, R.K., Rathod, A.D. et al. Idiopathic Myelofibrosis in an Infant. Indian J Pediatr 78, 734–736 (2011). https://doi.org/10.1007/s12098-010-0340-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12098-010-0340-6